1. Introduction {#sec1-molecules-23-02723}
===============

Inflammatory responses are widely implicated in vast kinds of acute and chronic human diseases, including cancer, atherosclerosis, and diabetes \[[@B1-molecules-23-02723]\]. Macrophages play a critical role and are involved in the self-regulating cycle of inflammation, as macrophages produce multiple pro-inflammatory cytokines and mediators that are involved in inflammation, such as the TNFα and the IL-6 \[[@B2-molecules-23-02723]\]. Interference therapy that target macrophages and related cytokines may be some new approaches for controlling inflammatory diseases.

Regulation of the inflammatory response depends on a variety of potential mechanisms, including peroxisome proliferator-activated receptors (PPARs) actions \[[@B3-molecules-23-02723]\]. PPARs are activated by their synthetic or natural ligands/modulators, which lead to the PPARs to bind to their specific DNA response elements, as heterodimers, with the retinoid X receptor (RXR) \[[@B4-molecules-23-02723]\]. PPARs have been found to have three subtypes, which are named PPARα, PPARβ/δ, and PPAR. They play crucial roles in the regulation of lipid and glucose metabolism. In addition, accumulating evidence reveals that activation of the PPARs are involved in the various types of inflammatory processes, due to the inhibition of pro-inflammatory genes expression and negative regulation of pro-inflammatory transcription factor signaling pathways, in inflammatory cells \[[@B5-molecules-23-02723]\]. Furthermore, activation of PPARs shows the anti-inflammatory effect by inhibiting the activation of nuclear factor-κB (NF-κB), leading to a decrease of pro-inflammatory cytokines and mediators \[[@B6-molecules-23-02723]\]. Therefore, PPARs have been shown to be the drug targets to treat various related inflammatory diseases, such as vascular diseases, cancer, and neurodegenerative diseases \[[@B7-molecules-23-02723]\]. Searching for the effective ligands or modulators of PPARs, for the prevention and clinical therapeutic options, is of great interest.

The natural product nuciferine ((*R*)-1,2-dimethoxyaporphine; Nuci) is an alkaloid found within the leaves of *Nymphaea caerulea* and *Nelumbo nucifera*, which is widely planted in Asia, the Middle East, and some countries in Africa \[[@B8-molecules-23-02723]\]. Especially in China, lotus leaves are usually commercially available for tea due to its pharmacologic effects, such as losing weight, heat-clearing, and detoxifying, according to the traditional theory of Chinese medicine \[[@B9-molecules-23-02723]\]. Recent studies showed that nuciferine, an important component of lotus leave extracts, can improve hepatic lipid metabolism \[[@B10-molecules-23-02723]\], increase the glucose consumption, and stimulate insulin secretion \[[@B11-molecules-23-02723]\]. Anti-inflammation activity of nuciferine was also reported in potassium oxonate-induced kidney inflammation \[[@B12-molecules-23-02723]\], as well as Fructose-induced inflammatory responses \[[@B13-molecules-23-02723]\], in vivo. However, the underlying molecular mechanisms of its anti-inflammatory effects are not fully understood. Based on the inflammatory-related functions of PPARs and the differences of the distinct tissue-specific expression, physiology, and ligand specificity of the PPARα, PPARβ/δ, and the PPARγ, the aim of this study was to investigate the effect of nuciferine on inflammation in lipopolysaccharide (LPS)-induced RAW264.7 cells and to observe if this effect is mediated by the three PPAR subtypes.

2. Results {#sec2-molecules-23-02723}
==========

2.1. Cytotoxicity of Nuciferine on RAW264.7 Cells {#sec2dot1-molecules-23-02723}
-------------------------------------------------

To test the effect of nuciferine on the cell viabilities of RAW264.7 cells, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed in RAW264.7 cells, using different concentrations of nuciferine, ranging from 1 to 50 μM. After treatment for 24 h, cell viabilities were measured, and the results are shown in [Figure 1](#molecules-23-02723-f001){ref-type="fig"}. Compared with the control group (without nuciferine), no significant difference (*p* \> 0.05) were found between control and all the treatment groups, indicating that nuciferine had no direct cytotoxicity, in this cell line. To avoid using a concentration of nuciferine higher than the normal physiological concentration, 10 μM was used in all of the following experiments.

2.2. Nuciferine Inhibited IL-6 and TNFα Production in LPS-Induced RAW264.7 Cells {#sec2dot2-molecules-23-02723}
--------------------------------------------------------------------------------

In order to evaluate whether the nuciferine has potential anti-inflammatory activity in RAW264.7 cells, the cells were pretreated with nuciferine (1\~50 µM), for 24 h, before exposure to LPS, and the pro-inflammatory cytokines IL-6 and TNFα were examined ([Figure 2](#molecules-23-02723-f002){ref-type="fig"}). Without the LPS stimulation, the concentrations of TNFα and IL-6, in the cell medium, by ELISA were 380.5 ± 51.3 pg/mL and 352.1 ± 60.1 pg/mL, respectively ([Figure 2](#molecules-23-02723-f002){ref-type="fig"}A,B). The LPS treatment significantly increased (*p* \< 0.05) both TNFα and IL-6 levels by 679.2% and 472.6%, respectively. Importantly, the nuciferine decreased both these cytokine levels induced by the LPS, in a dose-dependent manner. Meanwhile, gene expression of these cytokines, by RT-qPCR, showed the same trends as the ELISA results ([Figure 2](#molecules-23-02723-f002){ref-type="fig"}C,D). Pearson correlation analysis of both the protein and the mRNA levels of TNFα and IL-6, with the nuciferine concentrations, are shown in [Table 1](#molecules-23-02723-t001){ref-type="table"}. With the LPS treatment, it showed significant negative correlation of the ratio of nuciferine concentration versus IL-6 protein level (Pearson *r* = −0.62, *p* = 0.004, *n* = 20) or mRNA level (Pearson *r* = −0.50, *p* = 0.02, *n* = 20). Similarly, significant negative correlations were found between nuciferine concentration and TNFα protein level (Pearson *r* = −0.58, *p* = 0.02, *n* = 20) or mRNA level (Pearson *r* = −0.69, *p* = 0.01, *n* = 20). All these results indicated that nuciferine had a potential anti-inflammatory effect, by reducing inflammatory cytokines production.

2.3. Nuciferine Increased the PPARs Activity {#sec2dot3-molecules-23-02723}
--------------------------------------------

PPARs are involved in the various types of inflammatory processes \[[@B5-molecules-23-02723]\]. To study the potential molecular mechanism of nuciferine on the LPS-induced inflammation, we examined the effects of nuciferine on PPARs activity by a luciferase reporter assay. The cells were transfected with PPARs isoforms (PPARα/PPARδ/PPARγ) plasmid and reporter plasmid, followed by the treatment of nuciferine (1 or 10 µM) or PPARs agonists, for 24 h. All the selective agonists WY14643 for PPARα, GW501516 for PPARβ/δ, and rosiglitazone (Rosi) for PPARγ, significantly increased the fluorescence signal in the both the RAW264.7 cells and HEK 293 cells, confirming that the systems for detecting PPARs transactivation activity were correct. In the RAW 264.7 cells, nuciferine significantly increased the transcriptional activities of PPARα and PPARγ, in a dose-dependent manner, compared to control group. However, it did not affect PPARβ/δ activity ([Figure 3](#molecules-23-02723-f003){ref-type="fig"}A--C). Pearson correlation analysis ([Table 2](#molecules-23-02723-t002){ref-type="table"}) shows a significant positive correlation of the ratio of nuciferine concentration, versus the PPARα activity (Pearson *r* = 0.70; *p* = 0.004, *n* = 15) and a significant positive correlation of the ratio of nuciferine concentration versus the PPARγ activity (Pearson *r* = 0.51; *p* = 0.05, *n* = 15). However, there was no significant correlation of the ratio of nuciferine concentration versus the PPARβ/δ activity (Pearson *r* = 0.29; *p* = 0.11, *n* = 15). Meanwhile, the luciferase reporter assay was carried out using the HEK 293 cells ([Supplementary Figure S1](#app1-molecules-23-02723){ref-type="app"}) to verify the results. All the results showed that nuciferine increased the activities of the three PPARs but only significantly increased the PPARα and PPARγ activity. The mRNA levels of the targets genes of PPARs, such as carnitine palmitoyltransferase 1A (CPT-1A) for PPARα \[[@B14-molecules-23-02723]\], adipose differentiation related protein (ADRP) for PPARβ/δ \[[@B15-molecules-23-02723]\], CD36 for PPARγ \[[@B16-molecules-23-02723]\], were further investigated ([Figure 3](#molecules-23-02723-f003){ref-type="fig"}D). All these target genes expressions were up-regulated by nuciferine, at 10 μM, in the RAW264.7 cells. Together, these results indicated that nuciferine could enhance PPARs transcriptional activity in mononuclear macrophages.

2.4. Antagonists of PPARα and PPARγ Abolished the Anti-Inflammatory Effects of Nuciferine {#sec2dot4-molecules-23-02723}
-----------------------------------------------------------------------------------------

To further clarify whether the anti-inflammatory effect of nuciferine are mediated by PPARs, antagonists GW5417 for PPARα, GSK0660 for PPARβ/δ, GW9662 for PPARγ were co-administrated with nuciferine, for 24 h, in the LPS-induced RAW264.7 cells, respectively ([Figure 4](#molecules-23-02723-f004){ref-type="fig"}). As the results before, when stimulated with the LPS, the content of IL-6 and TNFα were increased. All these antagonists increased the pro-inflammatory cytokines, compared with the group treated with the LPS only. However, the effect of nuciferine was abolished in the presence of the PPARα and PPARγ antagonists, indicating that the anti-inflammatory effect of nuciferine, at least partially, went through the PPARs activation.

2.5. Nuciferine Decreased LPS Induced IκB-α Degradation through PPARs Activition {#sec2dot5-molecules-23-02723}
--------------------------------------------------------------------------------

PPARs exert anti-inflammatory effects by regulating the NF-κB signal pathway. To further investigate the mechanisms of nuciferine on anti-inflammatory effect, the degradation of IκB-α protein levels were determined with exposure to the nuciferine in the LPS-treated RAW 264.7 cells ([Figure 5](#molecules-23-02723-f005){ref-type="fig"}, original results see [Figure S2](#app1-molecules-23-02723){ref-type="app"}). When stimulated only with LPS, the cytosolic IκB-α protein was markedly degraded, consistent with the THP-1 treatment results \[[@B17-molecules-23-02723]\]. However, nuciferine treatment attenuated the pro-inflammatory effect of the LPS. Furthermore, the effects of nuciferine were abolished by a co-incubation with PPARs antagonists. The results suggested that nuciferine dramatically inhibited the LPS-induced NF-κB activation and its effect was PPARs-dependent.

3. Discussion {#sec3-molecules-23-02723}
=============

Our present study has shown that treatment with nuciferine ameliorates the LPS-induced inflammation in RAW264.7 cells. Importantly, it was found that the protective effect of nuciferine is mediated by PPARs activation. These results highlight the potential use of nuciferine for preventing inflammation.

Overexpression of the inflammatory mediators is closely associated with systemic injury. There is evidence that anti-inflammatory treatment has become an important component of inflammatory diseases \[[@B18-molecules-23-02723]\]. Inflammatory mediator inhibitors can be shown to have beneficial effects in improving the severity of inflammation-related diseases. A wide variety of phytochemicals derived from natural plant have anti-inflammatory effects, such as phenolics, terpenolids, and alkaloids \[[@B19-molecules-23-02723]\]. Nuciferine, an alkaloid found in the lotus leaves, exerted a protective effect against inflammation, in vivo \[[@B20-molecules-23-02723]\] and in vitro \[[@B21-molecules-23-02723]\]. Our results showed that nuciferine decreased the expression of inflammatory cytokines IL-6 and TNFα, in both protein and gene levels, dose dependently, in the LPS-treated RAW264.7 cells, indicating that nuciferine had potential anti-inflammatory effects.

Nuciferine, a natural alkaloid from the lotus leaves, have been reported to exert multiple beneficial effects, in vivo and in vitro, such as anti-tumor \[[@B22-molecules-23-02723]\] and insulin stimulatory effects \[[@B23-molecules-23-02723]\]. Our recent results showed that nuciferine improved the hepatic steatosis in high-fat diet/streptozocin-induced diabetic mice \[[@B24-molecules-23-02723]\]. Some studies reported that nuciferine suppressed the inflammation by regulating inflammatory signaling through different signal pathways. For example, in hyperuricemia mouse model, nuciferine inhibited renal inflammation through suppression of Toll-like receptor 4/myeloid differentiation factor 88/NF-κB signaling and a NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome \[[@B12-molecules-23-02723]\]. Similarly, in vitro studies, nuciferine exerted the anti-inflammatory and antilipemic effects, as well as the siRNA Per-Arnt-Sim kinase treatment group in oleic acid-induced hepatic steatosis, in HepG~2~ cells, indicating a potential molecular pathway of the anti-inflammation effect of nuciferine \[[@B21-molecules-23-02723]\]. As we know, the three subtypes of PPARs exert anti-inflammatory effects in vivo and in vitro by several different molecular mechanisms \[[@B25-molecules-23-02723],[@B26-molecules-23-02723],[@B27-molecules-23-02723]\]. PPARα \[[@B28-molecules-23-02723]\] and PPARγ \[[@B29-molecules-23-02723]\] were shown to repress some other transcription factors, such as NF-κB signal pathway, to reduce the release of inflammatory cytokines including IL-6 and TNFα, when they were activated by their ligands. The anti-inflammatory effects of PPARβ are mediated by ligand-independent repression \[[@B30-molecules-23-02723]\]. Owing to the anti-inflammatory effect of PPARs, we used the luciferase reporter assay and the target gene transcription of PPARα/PPARγ/PPARδ to test if the PPAR family is involved in the anti-inflammatory effect of nuciferine. The results showed that nuciferine activated the PPAR family, especially the PPARα and the PPARγ. Moreover, the antagonists of the PPAR family GW6417/GSK0660/GW9662 were treated in the cells to block the PPARs activities, before the nuciferine treatment. What's interesting is that all the antagonist treatment increased the inflammation markers. The protective effect of nuciferine was remarkably diminished by the inhibition of PPARα and PPARγ, indicating that the anti-inflammatory effect of nuciferine, at least in part, went through the PPARs receptor activation. To confirm these results, the protein expression of the activated PPARs and the total PPARs should also be tested, using immunoblotting, in the further studies. Our recent in vivo results also clarified that nuciferine-activated PPARα in the liver tissues, in a diabetic mouse model \[[@B24-molecules-23-02723]\]. Nuciferine is hydrophobic, consistent with the structures of most PPAR agonists. It could interact with the ligand-binding domain of PPARs, in theory, leading to the stabilization of the configuration of the hydrophobic core and subsequently the activation of PPARs to regulate the gene transcription \[[@B31-molecules-23-02723]\]. However, more binding mechanisms between the nuciferine and the PPARs should be further studied.

It is well known that NF-κB is an important target for inflammatory therapeutic strategy \[[@B32-molecules-23-02723]\]. PPARs have recently been shown to exert the anti-inflammatory activity by reducing the DNA-binding activity of NF-κB and suppressing its nucleus translocation, which attenuates the cytokine production and reduces tissue injury \[[@B32-molecules-23-02723],[@B33-molecules-23-02723],[@B34-molecules-23-02723]\]. NF-κB is a crucial factor to activate the inflammatory genes transcription, including pro-inflammatory cytokines, such as TNFα and IL-6 \[[@B35-molecules-23-02723]\]. In addition, IκBα expression was accompanied by a decrease in NF-κB DNA binding activity \[[@B36-molecules-23-02723]\]. Our results showed that nuciferine treatment alters the IκBα cellular content in LPS stimulation. Moreover, the specific inhibitors for PPARs reversed the effect of nuciferine, partially or completely, indicating that nuciferine could prevent IκBα degradation via PPARs activation, under the LPS stimulated conditions.

Overall, our studies demonstrated that nuciferine, with a concentration of 10 μM, attenuated the LPS-induced inflammation through activation of PPARs, especially PPAR-α and-γ, in RAW264.7 cells. These findings suggest that nuciferine may be a potentially important candidate for inflammatory diseases.

4. Materials and Methods {#sec4-molecules-23-02723}
========================

4.1. Reagents {#sec4dot1-molecules-23-02723}
-------------

Nuciferine (purity by HPLC \> 98.0%) was purchased from APP-CHEM (YHI-039, Xi'an, Shanxi, China). Dulbecco's modified Eagle's medium-high glucose (DMEM), fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and Lipofectamine 2000 reagent were purchased from Invitrogen (Carlsbad, CA, USA). Lipopolysaccharide (LPS), PPARs agonists WY14643, GW501516, rosiglitazone (Rosi) were purchased from Sigma (St. Louis, MO, USA). TRIzol reagent was purchased from Invitrogen (Carlsbad, CA, USA). IL-6 and TNF-α Mouse ELISA Kit was obtained from Elabscience Biotechnology Co. Ltd. (Wuhan, Hubei, China). Super Script II Rnase H Reverse Transcriptase kit was purchased from Invitrogen (Carlsbad, CA, USA).

4.2. Cell Culture {#sec4dot2-molecules-23-02723}
-----------------

Murine macrophage RAW264.7 cells (ATCC, Rockville, MD, USA) and human embryonic kidney cells (HEK293 cells, ATCC, Rockville, MD, USA) were cultured with DMEM containing 10% FBS, 100 U/mL penicillin, and 100 U/mL streptomycin. Cells were maintained at 37 °C, in a humidified atmosphere of 5% CO~2~ and 95% air. RAW264.7 cells were seeded into plates and treated at approximately 80% confluence.

4.3. Cytotoxicity {#sec4dot3-molecules-23-02723}
-----------------

RAW264.7 cells were seeded at a density of 1.5 × 10^3^ cells/well in 96-well plates. After 24 h, cells were treated with different concentrations of nuciferine (0--50 μM), for 24 h, followed by an addition 20 μL MTT solution (5 g/L), to each well, for 4 h. The insoluble formazan product was dissolved in 150 μL/well dimethyl sulfoxide (DMSO), after washing out the supernatant \[[@B37-molecules-23-02723]\]. Then, the absorbance at 490 nm was measured using a microplate reader (Olympus America Inc., New York, NY, USA). The percentage of cytotoxicity was calculated by the equation: Cytotoxicity (%) = (1 − A~490~ of sample)/A~490~ of control well.

4.4. IL-6 and TNFα Levels Determination {#sec4dot4-molecules-23-02723}
---------------------------------------

RAW264.7 cells were grown into 12-well plates, treated with different concentrations of nuciferine (0, 1, 10 or 50 μM) and stimulated with LPS (500 ng/mL). Cell-free supernatants were collected and the levels of pro-inflammatory cytokines, TNFα and IL-6 were measured using ELISA kits, by a determination of the absorbance at 450 nm, according to the manufacturer's instructions. Standard curves were used to calculate the concentration of TNFα and IL-6 in each sample.

4.5. PPARs Luciferase Reporter Assay {#sec4dot5-molecules-23-02723}
------------------------------------

HEK293T cells and RAW264.7 cells were plated into 12-well plates at 4 × 10^5^ cells/well without antibiotics. After 24 h at 60% confluence, cells were transfected according to the manufacturer's instructions. Briefly, PPARs isoforms (PPARα/PPARδ/PPARγ) plasmid (0.9 µg), reporter plasmid PPRE×3-TK-LUC (0.3 µg) and β-gal (0.1 µg) were transfected into the cells, using Lipofectamine 2000 reagents (1:1), for 4 h. Since transfection efficiency is typically low in RAW264.7 cells, more Lipofectamine 2000 was needed (1:2.5) and the transfection time was extended to 24 h. The medium was replaced with a complete media containing DMSO, nuciferine, or PPARs agonists, for 24 h. The cells were harvested and lysed to measure the luciferase activities using a luciferase assay kit, according to the manufacturer's instructions. The β-gal was transfected to normalize the transfection efficiency \[[@B38-molecules-23-02723]\].

4.6. RNA Isolation and Analysis {#sec4dot6-molecules-23-02723}
-------------------------------

Cells were cultured into 12-well plate with a density of 4 × 10^5^ cells/well. Total RNA was isolated using TRIzol reagent and reverse transcribed into cDNA. Real-time quantitative polymerase chain reaction (RT-qPCR) was performed as described by Yang et al. \[[@B39-molecules-23-02723]\]. Glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) was used as an internal control. Ct values of the sample were calculated, and the mRNA levels were analyzed by 2^−ΔΔCt^ method and normalized to *Gapdh* \[[@B40-molecules-23-02723]\]. The primer sequences were listed in [Supplemental Table S1](#app1-molecules-23-02723){ref-type="app"}.

4.7. Immunoblotting {#sec4dot7-molecules-23-02723}
-------------------

RAW264.7 Cell lysates were prepared using a lysis buffer containing 0.1% Triton X-100 and proteinase inhibitors (Roche, Nutley, NJ, USA). Protein concentrations were determined using the BCA protein assay kit (Thermo Scientific, PA, USA). Western blot was performed as described by Yang et al. \[[@B39-molecules-23-02723]\]. After blocking the membranes, primary rabbit antibody against IκBα (Santa Cruz Biotechnology, Dallas, TX, USA) was incubated with a ratio of 1:1000 overnight. β-actin (1:5000, Santa Cruz Biotechnology, Dallas, TX, USA) was used as a loading control. Membranes were then washed with TBST and incubated with the secondary antibodies conjugated to anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (1:3000, Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h. Bands were detected by enhanced chemiluminescence using ECL (Amersham Biosciences, Picataway, NJ, USA) and then visualized by X-ray films.

4.8. Data Statistics {#sec4dot8-molecules-23-02723}
--------------------

Quantitative data are expressed as mean ± SEM using SPSS 18.0 (IBM Corporation, Chicago, IL, USA). Student *t* test and ANOVA followed by Tukey's post hoc test were used to analyze the significant difference between two or more groups, respectively. The rank-based test methods were employed when data were not in a normal distribution or the variances were not homogeneous. All the results were representative of at least three independent experiments.

**Sample Availability:** Not available.

The following are available online, Figure S1: Effect of Nuciferine on PPARs transcription activities in HEK 293 cells. Figure S2: Original western blot films of [Figure 5](#molecules-23-02723-f005){ref-type="fig"}A. Table S1: Sequences of primers for qRT-PCR.

###### 

Click here for additional data file.
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![Cytotoxicity of Nuciferine on macrophage RAW264.7 cells. Cell viabilities of RAW264.7 cells treated with Nuciferine (0, 1, 3, 10 or 50 μM), for 24 h, were measured by MTT assay.](molecules-23-02723-g001){#molecules-23-02723-f001}

![Nuciferine inhibits the LPS-induced TNFα and IL-6 production in RAW264.7 cells. RAW 264.7 cells were pretreated with nuciferine (0, 1, 10 or 50 μM for 24 h) and then stimulated with the LPS (500 ng/mL for 12 h), with a nuciferine withdrawal. (**A**,**B**) TNFα and IL-6 releases and (**C**,**D**) mRNA level of TNFα and IL-6, respectively. \* *p* \< 0.05 \*\* *p* \< 0.01 vs. control, ^\#^ *p* \< 0. 05 ^\#\#^ *p* \< 0.01 vs. LPS treatment.](molecules-23-02723-g002){#molecules-23-02723-f002}

![Effect of Nuciferine on PPARs transcription activities. (**A**--**C**) Luciferase reporter assay in RAW264.7 cells. (**D**) The relative mRNA expression of PPARs target genes. \* *p* \< 0.05 \*\* *p* \< 0.01 vs. control.](molecules-23-02723-g003){#molecules-23-02723-f003}

![Antagonist of PPARα and PPARγ abolished the effects of nuciferine on the LPS-induced TNFα and IL-6 production. RAW264.7 cells were pretreated with GW6417/GSK0660/GW9662, for 12 h, followed by the nuciferine incubation, for 24 h, and then stimulated with LPS for 12 h. (**A**,**B**) production of the IL-6 and the TNFα in a cell medium supernatant. (**C**,**D**) mRNA expression of IL-6 and TNFα. \* *p* \< 0.05 \*\* *p* \< 0.01 vs. control. ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 vs. LPS treatment. ^\$^ *p* \< 0.05 vs. antagonist pretreatment followed by the LPS stimulation.](molecules-23-02723-g004){#molecules-23-02723-f004}

![Anti-inflammatory effects of nuciferine on the LPS-induced inflammatory response, are PPARs dependent. RAW264.7 cells were pretreated with GW6417/GSK0660/GW9662, for 12 h, followed by the Nuciferine incubation and then stimulated by the LPS with a nuciferine withdrawal. Levels of the expression of IκBα were detected by Western blotting. \* *p* \< 0.05 vs. control group; ^\#^ *p* \< 0.05 vs. LPS group.](molecules-23-02723-g005){#molecules-23-02723-f005}

molecules-23-02723-t001_Table 1

###### 

Nuciferine inhibits the LPS-induced TNFα and IL-6 production in RAW264.7 cells.

  --------------------------------------------------------------------------------------------------------------------
  Nuciferine\   LPS\      TNFα                      IL-6                                          
  (μM)          (ng/mL)                                                                           
  ------------- --------- ------------------------- -------------------- ------------------------ --------------------
  0             0         380.51 ± 51.27            0.99 ± 0.01          352.01 ± 60.02           1.01 ± 0.01

  0             500       2584.46 ± 179.60 \*       1.64 ± 0.21 \*\*     1663.71 ± 137.20 \*      3.34 ± 0.39 \*\*

  1             500       2315.98 ± 146.64          1.39 ± 0.17          1643.94 ± 209.69         2.59 ± 0.28

  10            500       2139.87 ± 275.53          1.05 ± 0.13 ^\#^     1216.91 ± 88.18 ^\#^     1.92 ± 0.20 ^\#\#^

  50            500       1772.82 ± 203.58 ^\#\#^   0.61 ± 0.11 ^\#\#^   1028.78 ± 74.61 ^\#\#^   1.85 ± 0.21 ^\#\#^
  --------------------------------------------------------------------------------------------------------------------

Quantitative data are presented as mean ± SEM. \* *p* \< 0.05 \*\* *p* \< 0.01 vs. control, ^\#^ *p* \< 0. 05 ^\#\#^ *p* \< 0.01 vs. LPS treatment.

molecules-23-02723-t002_Table 2

###### 

Effect of Nuciferine on PPARs transcription activities in RAW264.7 cells.

  Nuci (μM)   PPARα            PPARβ/δ          PPARγ
  ----------- ---------------- ---------------- ----------------
  0           1.03 ± 0.04      0.99 ± 0.01      1.02 ± 0.01
  1           1.34 ± 0.11 \*   1.03 ± 0.19      1.31 ± 0.09 \*
  10          1.44 ± 0.11 \*   1.13 ± 0.27      1.35 ± 0.12 \*
  agonist     1.69 ± 0.06 \*   1.17 ± 0.22 \*   1.57 ± 0.13 \*

Quantitative data are presented as mean ± SEM. \* *p* \< 0.05 vs. control.

[^1]: These authors contributed equally to this work.
